-
Mashup Score: 4First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA - 5 month(s) ago
Basil S Lewis; First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA, Eur
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 15PCSK9 Inhibitors: Tips and Tricks for Improving Access and Adherence - 5 month(s) ago
Do you know how to leap the barriers of access and adherence to proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and how to get your patients to goal?
Source: www.medscape.orgCategories: General Medicine News, Cardiology News and JournTweet-
Do you know how to leap the barriers of access and adherence to #PCSK9 inhibitors and how to get your patients to goal? Learn the tips and tricks from this 🆕 activity developed through a collaboration between the ACC and Medscape Education: https://t.co/PiTPfjFVhB https://t.co/ABXFB4UEOe
-
-
Mashup Score: 11PCSK9 Inhibitors: Tips and Tricks for Improving Access and Adherence - 6 month(s) ago
Do you know how to leap the barriers of access and adherence to proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and how to get your patients to goal?
Source: www.medscape.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Do you know how to leap the barriers of access and adherence to #PCSK9 inhibitors and how to get your patients to goal? Learn the tips and tricks from this 🆕 activity developed through a collaboration between the ACC and Medscape Education: https://t.co/PiTPfjFVhB https://t.co/ABXFB4UEOe
-
-
Mashup Score: 2
Corresponding Author
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet-
#PCSK9i quenching the flames of pyroptosis: more than just lipid lowering in chronic limb-threatening ischemia (CLTI)? Read the editorial by Drs. Okazaki & @NaomiHamburg on the new #JACCBTS study about a novel role for #PCSK9 in CLTI pathophysiology: https://t.co/oxnZhnInzE https://t.co/OgWXlsNhRW
-
-
Mashup Score: 4PCSK9 Promotes Hypoxia-Induced EC Pyroptosis by Regulating Smac Mitochondrion-Cytoplasm Translocation in Critical Limb Ischemia: - 7 month(s) ago
Highlights • Hypoxia-induced EC death and impaired angiogenesis are the main pathophysiological features of CLI. However, existing treatments have failed to significantly improve CLI. Therefore, it…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet-
#PCSK9 promotes #hypoxia-induced endothelial cell pyroptosis by regulating Smac mitochondrion-cytoplasm translocation in critical limb ischemia. Read about this novel role for PCSK9 in the new #JACCBTS study by Drs. Zhang, Liang, & colleagues: https://t.co/TJ1ear74JH https://t.co/9XAelZzCKg
-
-
Mashup Score: 1Rare Protein-Truncating DNA Variants in APOB or PCSK9, LDL Cholesterol Level, and Risk of Coronary Heart Disease - 1 year(s) ago
This genetic association study evaluates the association of protein-truncating variants in APOB and PCSK9 with low-density lipoprotein (LDL) cholesterol levels and coronary heart disease.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
Association of Rare Protein-Truncating DNA Variants in APOB or #PCSK9 With #LDL and #MACE : “it’s the ApoB stupid! “ #plagiarism #Quote https://t.co/IxgYpfKjwN
-
-
Mashup Score: 0Trends in Lipid-Lowering Prescriptions: Increasing Use of Guideline-Concordant Pharmacotherapies, U.S., 2017‒2022 - 1 year(s) ago
Almost one third of U.S. adults have elevated low-density lipoprotein cholesterol, increasing their risk of atherosclerotic cardiovascular disease. The 2018 American College of Cardiology/American Heart Association Multisociety Cholesterol Management Guideline recommends maximally tolerated statin for those at increased atherosclerotic cardiovascular disease risk and add-on therapies (ezetimibe…
Categories: Cardiologists, Latest HeadlinesTweet-
Patients filling moderate- & high-intensity #statins and add-on ezetimibe and #PCSK9 inhibitors have ⬆️, indicating uptake of #guideline-concordant lipid-lowering therapies. #prevention #cholesterol #LDL @CDCgov @NIH_NHLBI #HeartDisease #AJPM https://t.co/pGqd0l3L1F https://t.co/N3RGQeuH6V
-
-
Mashup Score: 4Oral PCSK9 Inhibitor Shows Encouraging LDL Lowering - 1 year(s) ago
A new oral formulation of a PCSK9-inhibitor, cholesterol-lowering drug has shown encouraging results in a phase 2 study.
Source: MedscapeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
According to a #JACC study presented at #ACC23/#WCCardio, a new oral formulation of #PCSK9 had promising results for lowering LDL #cholesterol. @SueHughes8 covers the findings in @Medscape: https://t.co/2BOGsxC4y0
-
-
Mashup Score: 0Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study - 1 year(s) ago
The drug, MK-0616, was effective and well tolerated in patients with a variety of ASCVD risks. Phase III plans are now afoot.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
An investigational oral #PCSK9 inhibitor has shown promise for patients with #hypercholesterolemia with a range of (#ASCVD) risks in a phase IIb trial Phase III plans are now afoot. #TCTMD @TCTMD @ToddNeale @mmamas1973 @ShelleyWood2 @BethFratesMD https://t.co/7h5j7ULPPY
-
-
Mashup Score: 0
NEW ORLEANS — In a phase 2 trial, an oral PCSK9 inhibitor lowered LDL about the same amount observed with injectable PCSK9 inhibitors for 8 weeks, researchers reported at the American College of Cardiology Scientific Session.For the phase 2b, randomized, double-blind, placebo-controlled trial, researchers evaluated safety and efficacy of the oral PCSK9 inhibitor (MK-0616, Merck) in patients
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
An oral #PCSK9 was found to reduce LDL #cholesterol in a similar rate to injectable PCSK9 inhibitors, according to research reported at #ACC23/#WCCardio. Find out more in @CardiologyToday: https://t.co/BoykROJ66c
-
RT @FeliceGragnano: #PCSK9 gene editing therapy for lowering LDL-C: New frontier in CV pharmacotherapy? https://t.co/miLDTXfJdb #EHJPharma…